Clinical trials: Non Alcoholic Fatty Liver
NAFLD, Hepatocellular Carcinoma
Utilization of MAsS in Patients Undergoing LT for HCC
The aim of this study is to determine the effects of liver transplantation and standard immunosuppression on body composition in patients with compensated cirrhosis and hepatocellular carcinoma.
- Conditions
- NAFLD, Hepatocellular Carcinoma, Liver Diseases, Liver Cancer
- Trial name
- NCT05184283
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Columbia University
Non-alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis
This pilot study aims to investigate whether 6 weeks of twice weekly High-intensity Interval Training (HIT) results in improvements in disease-specific measures, feelings of general well-being, physical fitness and cognitive…
- Trial name
- NCT02528305
- Testing
- High-intensity Interval Training
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Bath
Non-alcoholic Fatty Liver Disease, NAFLD
Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease
There is a significant association between autonomic dysfunction and symptoms experienced by NAFLD patients mediated by increased systemic inflammation and insulin resistance, resulting in deteriorating quality of life of…
- Conditions
- Non-alcoholic Fatty Liver Disease, NAFLD, Fatty Liver, Nonalcoholic, Nonalcoholic Fatty Liver Disease
- Trial name
- AD-NAFLD (NCT02132780)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Virginia Commonwealth University
Fatty Liver Disease
Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue Assessment
Non-alcoholic fatty liver disease (NAFLD) has become a major health problem worldwide with an increasing prevalence ranging from 13% in Africa to 42% in South-East Asia.
- Trial name
- Fatty liver (NCT05694923)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Egypt
- Volunteers
- 55 people
- Sponsor
- Assiut University
Nonalcoholic Fatty Liver Disease (NAFLD)
Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease
The aim of this current study was to assess the therapeutic effects of perindopril and telmisartan for hypertensive patients with NAFLD and make comparison between the therapeutic effects of these two kind of drugs.
- Trial name
- NF-NAFLD (NCT02213224)
- Testing
- Perindopril, Telmisartan, Amlodipine
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Metabolic Syndrome X
Evaluation of the Effects of a L.Reuteri Strain on Markers of Inflammation, Cardiovascular Risk and Fatty Liver Disease
The purpose of this study is the evaluation of the effects in obese patients with metabolic syndrome on the composition of the intestinal microbiota, markers of the syndrome (hypertension, dyslipidemia, inflammation biomarkers…
- Trial name
- PROSIR (NCT02972567)
- Testing
- Lactobacillus spp, Control
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Biosearch S.A.
Metabolic Disease, Fatty Liver, Nonalcoholic
Evaluation of the Effects of Orange Consumption on Carbohydrate and Lipid Metabolism in Subjects With MAFLD (Metabolic Associated Fatty Liver Disease)
Given the current increase in the incidence of dyslipidemia and obesity in the general population, there is a strong interest in identifying dietary factors capable of preventing the onset of metabolic diseases or at least…
- Trial name
- NCT05558592
- Testing
- Dietary supplementation with fresh oranges, Balanced Diet without oranges
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Obesity, Liver Diseases
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting…
- Conditions
- Obesity, Liver Diseases, Liver Fibrosis, Liver Fat
- Trial name
- NCT06138821
- Testing
- ESG + lifestyle modification, Lifestyle modification
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Pichamol Jirapinyo, MD, MPH
Non-Alcoholic Fatty Liver Disease
Effect of Multi Vitamin and Mineral Supplementation of Liver Enzymes and Sonography in Patient With NAFLD
The study was performed on 160 participants, to ensure the impact of multi vitamin and mineral to reduce NAFLD
- Trial name
- NCT05897606
- Testing
- Multiviamins and minerals
- Where
- Iraq
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Sulaimani Polytechnic University
Non-alcoholic Fatty Liver Disease
Prospective Cohort Study in Patients With NAFLD
To assess the importance of intracellular signalling pathways and its deregulation in adiposity and diabetes-related insulin resistance, liver tissue samples of patients suffering from non-alcoholic fatty liver disease (NAFLD)…
- Trial name
- NCT00575133
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- University of Zurich
Non Alcoholic Steatohepatitis
Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
The study was being conducted in order to assess the pharmacokinetics and the safety of elafibranor following once daily administration of two dose levels of elafibranor (80 milligrams [mg] and 120mg) during 3 months in children…
- Trial name
- NCT03883607
- Testing
- Elafibranor 80mg, Elafibranor 120mg
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Genfit
Non Alcoholic Steatohepatitis, Hyperuricemia
Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia
This study aims at evaluating and comparing the protective outcomes of using Febuxostat versus Vitamin E in Hyperuricemia non-alcoholic steatohepatitis patients without cirrhosis.
- Trial name
- NCT05574036
- Testing
- Febuxostat 80 MG Oral Tablet, vit E
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Tanta University
Overweight, Microtia
Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans
Previous work of the investigators demonstrated the anti-obesity and anti-steatosis potential of the Amazonian fruit camu-camu (CC) in a mouse model of diet-induced obesity [1].
- Conditions
- Overweight, Microtia, Endotoxemia, Metabolic Syndrome
- Trial name
- NCT04130321
- Testing
- Camu camu
- Where
- Canada
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Laval University
Non Alcoholic Steatohepatitis
Efficacy and Safety of Montelukast in Non Alcoholic Steatohepatitis (NASH)
the current study is to evaluate the efficacy and safety of Montelukast in the treatment of patients with non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT04537780
- Testing
- Montelukast
- Where
- Egypt
- Volunteers
- 44 people
- Sponsor
- Tanta University
Non-Alcoholic Fatty Liver Disease, Metabolic Encephalopathy
Prognostic Significance of Fatty Liver Disease in Bariatric Patients
Prospective non-randomized intervention case control study on patients with a BMI > 35. The intervention group/cases (n=600) is comprised of bariatric patients who undergo bariatric surgery and the control group (n=600) of age…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Metabolic Encephalopathy, Obesity, Morbid, Non-alcoholic Steatohepatitis
- Trial name
- PROMETHEUS (NCT03535142)
- Testing
- Bariatric surgery
- Where
- Denmark
- Volunteers
- 1,200 people
- Sponsor
- Esbjerg Hospital - University Hospital of Southern Denmark
Non Alcoholic Fatty Liver Disease
Study to Investigate the Effect of L. Lactis CKDB001 Administration on Liver Aminotransferases in Subjects With NAFLD
A study for evaluating the safety and efficacy of L. lactis CKDB001 on liver aminotransferases in subjects with nonalcoholic fatty liver disease
- Trial name
- NCT07378280
- Testing
- Probiotics (L. lactis CKDB001)
- Where
- South Korea
- Volunteers
- 95 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Non Alcoholic Fatty Liver Disease, Steatohepatitis
Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease
To explore whether there is a different response to omega-3 fatty acid rich diet with respect to the hepatic fat fraction % (HFF), triglyceride, and ALT levels between the rs738409 minor allele (GG) and the common allele…
- Conditions
- Non Alcoholic Fatty Liver Disease, Steatohepatitis, Hypertriglyceridemia, Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1
- Trial name
- NCT01556113
- Testing
- Omega diet
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Yale University
Overweight and Obesity, Child Obesity
Fruit and Vegetable Products Enriched With Fibre From Potato Starch With Prebiotic Properties for Children and Youth
The main goal of the project is to test fruit and vegetable mousse, with the addition of a fiber preparation made of potato starch with prebiotic properties, on selected clinical, metabolic and immunological parameters in…
- Conditions
- Overweight and Obesity, Child Obesity, Hypertension, NAFLD
- Trial name
- NCT05140070
- Testing
- Vegetable and fruit mousse enriched with a fiber preparation from potato starch with prebiotic properties, Vegetable and fruit mousse, Dietary and physical activity counselling
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Children's Memorial Health Institute, Poland
Nonalcoholic Fatty Liver Disease
Treatment of Nonalcoholic Fatty Liver Disease With Probiotics and Prebiotics
The investigators' aim is to determine whether probiotic and prebiotic treatment plus lifestyle advice is more effective in reducing hepatic fat content than lifestyle advice alone in patients with Nonalcoholic Fatty Liver…
- Trial name
- NCT00870012
- Testing
- Lepicol probiotic & prebiotic formula, Simple lifestyle advice
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese University of Hong Kong
Non-alcoholic Fatty Liver Disease
Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH
The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated.
- Trial name
- SKYLINE (NCT06104319)
- Testing
- GSK4532990
- Where
- 14 sites in United States
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.